The kidney biopsy is the standard of care for diagnosis of lupus nephritis and remains necessary to ensure accurate diagnosis and guide treatment. Repeat biopsy should be considered when therapy modifications are necessary, as in cases with incomplete or no response, or when stopping therapy for those in remission. There are several promising biomarkers of kidney disorders; however, these markers need to be validated in a prospective clinical trial before being applied clinically. Molecular analysis may provide the information presently lacking from current evaluation of kidney disorders and may better inform on prognosis and treatment considerations.
Key points
- •
The kidney biopsy is the standard of care for diagnosis of lupus nephritis and remains necessary to ensure accurate diagnosis and guide treatment.
- •
Repeat biopsy should be considered when therapy modifications are necessary, as in cases with incomplete or no response, or when stopping therapy for those in remission.
- •
There are several promising biomarkers of kidney disorders; however, these markers needed to be validated in a prospective clinical trial before being applied clinically.
- •
Molecular analysis may provide the information presently lacking from current evaluation of kidney disorders and may better inform prognosis and treatment considerations.
Related posts:
Systemic Lupus Erythematosus
The Immunopathology of Cutaneous Lupus Erythematosus
Impact of Race and Ethnicity in the Course and Outcome of Systemic Lupus Erythematosus
Pathogenesis and Treatment of Atherosclerosis in Lupus
Systemic Lupus Erythematosus and Malignancies
Post-marketing Experiences with Belimumab in the Treatment of SLE Patients
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
